Actinic Keratosis- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025
This report can be delivered to the clients within 5 days
DelveInsight’s “Actinic Keratosis– Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025”report provides the comprehensive insights on the competitive landscape and market of Actinic Keratosis (AK).
The Report covers an overview of the disease and global market trends of the Actinic Keratosis for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Actinic Keratosis from 2017 to 2025 segmented by seven major markets. The market size covered in our report is based only upon the topical therapies approved for Actinic Keratosis which represents around 5% of the total market size of Actinic Keratosis.
In addition, the report also includes global forecast of epidemiology of Actinic Keratosis till 2025.The Report also covers market drivers, market barriers and unmet medical need.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Actinic Keratosis pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/ Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
United States accounts for the highest number of prevalent cases of Actinic Keratosis as compared to EU5 and Japan. As per DelveInsight forecasts, 76,603,272 cases of Actinic Keratosis were prevalent in the United States in the year 2015. This number is expected to grow at a CAGR of XX% from 2015 to 2025.
The Topical Therapy of Actinic Keratosis considered in our report include Ingenol mebutate, Diclofenac 3%, Imiquimod 5%, 5-Fluorouracil 5%, Imiquimod 3.75% and Fluorouracil/Salicylic acid combination. Patient adherence is generally low, around 50%-55% when it comes to topical treatment. High percentage of non-adherence to the regimen has been observed amongst the patients opting for topical therapy owing to the long treatment duration. The procedural therapy still remains the standard of care.
United States contributes the major share of the Actinic keratosis(AK) market as compared to EU5 countries and Japan. According to DelveInsight estimation, the market size of Actinic Keratosis (topical therapies only) in the United States, was estimated to be USD 102.62 Millions in 2015 and is expected to grow at a CAGR of XX% from 2015 to 2025.
SCOPE
DelveInsight’s “Actinic Keratosis– Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025”report provides the comprehensive insights on the competitive landscape and market of Actinic Keratosis (AK).
The Report covers an overview of the disease and global market trends of the Actinic Keratosis for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Actinic Keratosis from 2017 to 2025 segmented by seven major markets. The market size covered in our report is based only upon the topical therapies approved for Actinic Keratosis which represents around 5% of the total market size of Actinic Keratosis.
In addition, the report also includes global forecast of epidemiology of Actinic Keratosis till 2025.The Report also covers market drivers, market barriers and unmet medical need.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Actinic Keratosis pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/ Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
United States accounts for the highest number of prevalent cases of Actinic Keratosis as compared to EU5 and Japan. As per DelveInsight forecasts, 76,603,272 cases of Actinic Keratosis were prevalent in the United States in the year 2015. This number is expected to grow at a CAGR of XX% from 2015 to 2025.
The Topical Therapy of Actinic Keratosis considered in our report include Ingenol mebutate, Diclofenac 3%, Imiquimod 5%, 5-Fluorouracil 5%, Imiquimod 3.75% and Fluorouracil/Salicylic acid combination. Patient adherence is generally low, around 50%-55% when it comes to topical treatment. High percentage of non-adherence to the regimen has been observed amongst the patients opting for topical therapy owing to the long treatment duration. The procedural therapy still remains the standard of care.
United States contributes the major share of the Actinic keratosis(AK) market as compared to EU5 countries and Japan. According to DelveInsight estimation, the market size of Actinic Keratosis (topical therapies only) in the United States, was estimated to be USD 102.62 Millions in 2015 and is expected to grow at a CAGR of XX% from 2015 to 2025.
SCOPE
- Overview of the Global pipeline scenario for Actinic Keratosis, products and associated companies information
- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
- Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
- To understand the future market competition in the global Actinic Keratosis market and Insightful review of the key market drivers and barriers.
- The report will help in developing business strategies by understanding the trends shaping and driving the global Actinic Keratosis market.
- Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
- The Report also covers the detailed global historical and forecasted Actinic Keratosis market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
Report Introduction
Actinic Keratosis Market Overview at a Glance
Global Market Size of Actinic Keratosis in 2016
Global Market Size of Actinic Keratosis in 2025
Actinic Keratosis: Overview
Causes
Signs and symptoms
Risk Factors
Pathophysiology/ Mechanisms of action
Diagnosis
Epidemiology and Patient Population
Assumptions and Caveats
United States
Prevalent Population of Actinic Keratosis in United States (2015-2025)
Europe
Germany
Prevalent Population of Actinic Keratosis in Germany (2015-2025)
Italy
Prevalent Population of Actinic Keratosis in Italy (2015-2025)
Spain
Prevalent Population of Actinic Keratosis in Spain (2015-2025)
France
Prevalent Population of Actinic Keratosis in France (2015-2025)
United Kingdom
Prevalent Population of Actinic Keratosis in United Kingdom (2015-2025)
Japan
Prevalent Population of Actinic Keratosis in Japan (2015-2025)
Treatment Algorithm
Lesion-Directed Therapies:
Field-Directed Therapies
Photodynamic therapy
Competitive Marketed Drug Landscape
Ameluz (aminolevulinic acid hydrochloride): Biofrontera Pharma
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy
Product Profile
Marketed Drug List Continued…
Competitive Pipeline Landscape
Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Actinic Keratosis: Region-Specific Market Analysis
Region-Specific Market Distribution and Comparison
Overview on Actinic Keratosis Market (2016)
Overview on Actinic Keratosis Market (2025)
Global Market Outlook –Actinic Keratosis
United States
Market Outlook
Market Size
Europe
Market Outlook
Germany
Market Size
France
Market Size
Italy
Market Size
Spain
Market Size
United Kingdom
Market Size
Japan
Market Outlook
Market Size
Market Drivers
Market Restraints
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Actinic Keratosis Market Overview at a Glance
Global Market Size of Actinic Keratosis in 2016
Global Market Size of Actinic Keratosis in 2025
Actinic Keratosis: Overview
Causes
Signs and symptoms
Risk Factors
Pathophysiology/ Mechanisms of action
Diagnosis
Epidemiology and Patient Population
Assumptions and Caveats
United States
Prevalent Population of Actinic Keratosis in United States (2015-2025)
Europe
Germany
Prevalent Population of Actinic Keratosis in Germany (2015-2025)
Italy
Prevalent Population of Actinic Keratosis in Italy (2015-2025)
Spain
Prevalent Population of Actinic Keratosis in Spain (2015-2025)
France
Prevalent Population of Actinic Keratosis in France (2015-2025)
United Kingdom
Prevalent Population of Actinic Keratosis in United Kingdom (2015-2025)
Japan
Prevalent Population of Actinic Keratosis in Japan (2015-2025)
Treatment Algorithm
Lesion-Directed Therapies:
Field-Directed Therapies
Photodynamic therapy
Competitive Marketed Drug Landscape
Ameluz (aminolevulinic acid hydrochloride): Biofrontera Pharma
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy
Product Profile
Marketed Drug List Continued…
Competitive Pipeline Landscape
Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Actinic Keratosis: Region-Specific Market Analysis
Region-Specific Market Distribution and Comparison
Overview on Actinic Keratosis Market (2016)
Overview on Actinic Keratosis Market (2025)
Global Market Outlook –Actinic Keratosis
United States
Market Outlook
Market Size
Europe
Market Outlook
Germany
Market Size
France
Market Size
Italy
Market Size
Spain
Market Size
United Kingdom
Market Size
Japan
Market Outlook
Market Size
Market Drivers
Market Restraints
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
Table 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
Table 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
Table 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
Table 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
Table 8: Ingenol Disoxate, Clinical Trials by Zone, 2017
Table 9:Clinical Trials by Recruitment status, 2017
Table 10: Number of Products under development by Companies, 2017
Table 11: Clinical Stage Products, 2017
Table 12: Pre-Clinical Stage Products, 2017
Table 13: Assessment by Monotherapy Products, 2017
Table 14: Assessment by Combination Products, 2017
Table 15: Assessment by Route Of Administration, 2017
Table 16: Assessment by Stage and Route Of Administration, 2017
Table 17: Assessment by Molecule Type, 2017
Table 18: Assessment by Stage and Molecule Type, 2017
Table 19: Assessment by Stage of development and Domain, 2017
Table 20: Assessment by Stage of development and Domain, 2017
Table 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
Table 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
Table 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
Table 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
Table 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
Table 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
Table 8: Ingenol Disoxate, Clinical Trials by Zone, 2017
Table 9:Clinical Trials by Recruitment status, 2017
Table 10: Number of Products under development by Companies, 2017
Table 11: Clinical Stage Products, 2017
Table 12: Pre-Clinical Stage Products, 2017
Table 13: Assessment by Monotherapy Products, 2017
Table 14: Assessment by Combination Products, 2017
Table 15: Assessment by Route Of Administration, 2017
Table 16: Assessment by Stage and Route Of Administration, 2017
Table 17: Assessment by Molecule Type, 2017
Table 18: Assessment by Stage and Molecule Type, 2017
Table 19: Assessment by Stage of development and Domain, 2017
Table 20: Assessment by Stage of development and Domain, 2017
Table 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
Table 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
Table 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
LIST OF FIGURES
Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
Figure 9:Clinical Trials by Recruitment status, 2017
Figure 10: Number of Products under development by Companies, 2017
Figure 11: Clinical Stage Products, 2017
Figure 12: Pre-Clinical Stage Products, 2017
Figure 13: Assessment by Monotherapy Products, 2017
Figure 14: Assessment by Combination Products, 2017
Figure 15: Assessment by Route Of Administration, 2017
Figure 16: Assessment by Stage and Route Of Administration, 2017
Figure 17: Assessment by Molecule Type, 2017
Figure 18: Assessment by Stage and Molecule Type, 2017
Figure 19: Assessment by Stage of development and Domain, 2017
Figure 20: Assessment by Stage of development and Domain, 2017
Figure 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
Figure 9:Clinical Trials by Recruitment status, 2017
Figure 10: Number of Products under development by Companies, 2017
Figure 11: Clinical Stage Products, 2017
Figure 12: Pre-Clinical Stage Products, 2017
Figure 13: Assessment by Monotherapy Products, 2017
Figure 14: Assessment by Combination Products, 2017
Figure 15: Assessment by Route Of Administration, 2017
Figure 16: Assessment by Stage and Route Of Administration, 2017
Figure 17: Assessment by Molecule Type, 2017
Figure 18: Assessment by Stage and Molecule Type, 2017
Figure 19: Assessment by Stage of development and Domain, 2017
Figure 20: Assessment by Stage of development and Domain, 2017
Figure 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
Figure 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
